
First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer
Researchers at Rice University, in collaboration with The University of Texas MD Anderson Cancer Center and clinical partners, have reported results from a first-in-human trial evaluating a novel cell-based platform for localized delivery of interleukin-2 (IL-2) in patients with advanced ovarian cancer.





